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 ABSTRACT 
 Background: The number of migraine patients eligible for preventive treatment is considerably higher than the number of patients 
actually using it. This study explores reasons for this discrepancy.
 Methods: An explorative survey among patients and their general practitioners (GPs) participating in a trial on preventive medica-
tion. Migraine patients who were eligible for preventive treatment ( n    75) attended an evaluation consultation with their GP to 
optimize migraine treatment. GPs and patients who did not start preventive treatment were asked if they had discussed the pos-
sibility of preventive treatment and, if so, why they decided not to start it. 
 Results: Of the 32 GPs, 8 (25%) did not discuss the possibility of preventive treatment with their patients; in 4 because of perceived 
lack of eff ectiveness. Patients who did not start preventive treatment ( n    43) used less triptans and had less psychological distress 
compared to those who did start ( n    32). Main reasons for patients not starting were negative attitudes towards medication in 
general, fear of medication side-eff ects, previous unsuccessful attempts, attacks not being severe enough, and impact of migraine 
on daily life acceptable. 
 Conclusion: The decision of the individual patient and their GP to start preventive treatment is not only determined by attack fre-
quency, but also depends on the impact of the headache attacks on their daily life and their negative attitude towards medication. 
 Key words: migraine, preventive treatment, profylaxis, general practice, acceptance 
 INTRODUCTION 
 Migraine is a common, disabling headache disorder with 
lifetime prevalence of 14% (1). In the Netherlands, 25% 
of women and 7.5% of men experience a migraine attack 
each year (2). Migraine leads to loss of quality of life and 
productivity both during and between attacks, causing a 
high socio-economic burden (3,4). In many guidelines on 
migraine treatment, a frequency of two or more attacks 
each month is an important starting point for discussing 
preventive treatment (5 – 9). Although    5% of migraine 
patients suff er from two or more attacks each month 
and should be considered for preventive treatment, only 
8 – 12% actually uses it (2,4,10 – 12). In the Netherlands, 
over 50% of migraine patients experiencing two or more 
attacks each month in general practice wishes to try pre-
ventive treatment, but have not discussed this with their 
general practitioner (GP) (12). 
 This study explores reasons for the discrepancy 
between the number of patients eligible for preventive 
treatment and the number of patients actually using it. 
 METHODS 
 Study group 
 The study group consisted of migraine patients who par-
ticipated in the LIMIT study; details on this study are 
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published elsewhere (13). Theoretically, participants 
may diff er from patients in general. However, partici-
pants of the LIMIT study did not diff er from non 
participants in terms of age, sex, triptan use at baseline, 
triptans prescribed during the study period, consulta-
tions for headache in the previous year, HIT-6 score, 
EuroQol score and use of prophylactic medication at 
baseline or 12 months (13). 
 The study was approved by the Ethical Committee of 
the Leiden University Medical Centre. In this pragmatic 
randomized trial, a proactive approach to migraine 
patients by their GP was compared with usual care. GPs 
in the intervention group received two training sessions 
of three hours each from two specialized GPs. The pro-
tocol was based on the headache guideline of the Dutch 
College of General Practitioners (5). The GP training 
included diagnostic criteria for headache (migraine, ten-
sion-type headache, and medication-overuse headache), 
acute and prophylactic treatment, and treatment of 
medication-overuse headache. Patients in the interven-
tion group were invited for an evaluation consultation 
with their GP to optimize their migraine treatment 
according to the headache guideline of the Dutch Col-
lege of General Practitioners. The guideline states that 
patients who experience two or more headache attacks 
per month should be off ered preventive therapy (5). 
However, in the LIMIT study 43 (57%) participants, 
who experienced two or more headache attacks per 
month according to their headache diary, did not start 
preventive therapy after this evaluation consultation 
(Figure 1). 
 Characteristics of the study group 
 The 43 patients who attended the evaluation consulta-
tion and reported two or more headache attacks per 
month, but did not start preventive treatment, were 
compared with the 32 patients who reported two or 
more headache attacks per month and did start pre-
ventive treatment. The following characteristics were 
compared: sex, age, impact of headache — using the 
HIT-6 questionnaire, score range 36 (no headache) to 78 
(very severe headache) (14); psychological distress — 
using the K10 questionnaire, score range 10 (no distress) 
to 50 (severe distress) (15); number of headache attacks, 
number of headache days per month, hours of paid work 
per month, and absence from work (days per month). 
Data on prescription of triptans and preventive medica-
tion, as well as consultation data, were collected from 
the electronic patient record. 
 Outcome measures 
 Patients. Patients were asked to complete a question-
naire about their reasons for not starting with preventive 
treatment (Supplementary Appendix 1 to be found 
online at http://www.informahealthcare.com/doi/ejgp/
10.3109/13814788.2012.708332). They were asked if 
they were aware of the possibility of preventive treat-
ment, and if this option was discussed during the evalu-
ation consultation, and who initiated this discussion 
(patient or GP). In case of not starting prophylaxis, they 
were asked why they decided not to raise the subject of 
preventive treatment, or not to start it after having dis-
cussed the subject. 
 GPs. GPs completed a questionnaire on each patient 
(Supplementary Appendix 1 to be found online at http://
www.informahealthcare.com/doi/ejgp/10.3109/138147
88.2012.708332). They were asked if they had discussed 
preventive treatment during the evaluation consultation 
and who had initiated this discussion. When applicable, 
they indicated why they had decided not to raise the 
subject, or decided not to start preventive treatment 
after having discussed the subject with the patient. 
 Analyses 
 Statistical analyses were performed with the SPSS statis-
tical package, using the independent the sample t-test 
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 RESULTS 
 Starters versus non-starters 
 Table I presents data on patients starting and not starting 
preventive treatment. At baseline, patients who did not 
start preventive treatment used less triptans and had a 
lower score on the K10 (indicating a lower level of psy-
chological distress). No other diff erences were found. 
 Patients 
 The questionnaire was completed by 31 of 43 patients 
(72%) (Figure 2). Responders and non-responders did 
not diff er regarding sex, age, HIT-6 score, K10 score, 
mean number of triptans prescribed per month during 
the last year, number of consultations for headache dur-
ing the last year, number of headache attacks, and num-
ber of headache days (data not shown). 
 Of the 31 responders, 13 (42%) had discussed the 
possibility of preventive treatment with their GP. In all 
but one case, the GP initiated the conversation about 
preventive treatment. Of the 18 patients who did not 
discuss preventive treatment with their GP, 7 (39%) were 
aware of the option but did not raise the subject. 
 The main reason for not raising the subject of pre-
ventive medication was that the patient had already 
tried this in the past (Table II). The main reasons for 
patients not starting preventive treatment after having 
discussed the issue with their GP were: a negative atti-
tude against medication in general, fear of side-eff ects, 
migraine attacks not being severe enough, acceptable 
infl uence of migraine on their daily life, past usage of 
preventive treatment, and the desire to opt for diff erent 
treatment fi rst (Table II). 
 GPs 
 The questionnaire was completed by 16 GPs with regard 
to 33 patients (Figure 3). In 8 cases (24%), preventive 
treatment was not discussed during the consultation. 
In all other 25 consultations, the physician raised the 
subject. 
 The main reason for not raising the subject was that 
the physician did not expect preventive treatment to 
have a positive eff ect on attack frequency or severity 
(Table II). Other reasons were: attempt to optimize attack 
treatment fi rst, try alternative treatment fi rst (e.g. phys-
iotherapy), and non-attendance at the follow-up consul-
tation to start preventive treatment. The main reasons 
for not starting preventive treatment after having 
discussed the issue with the patient were that patients 
were content with their present treatment or were 
not suffi  ciently motivated for preventive treatment 
(Table II). 
 In 4 cases the GP, after having checked the elec-
tronic patient record, reported that preventive treat-
ment was discussed, whereas the patient reported 
that it was not discussed. This suggests recall bias 
among the patients. In 3 of these 4 cases, the GP 
reported not to have started preventive treatment 
because the patient did not want to use medication 
on a daily basis. In one case, the migraine attacks were 
not severe enough. 
 DISCUSSION 
 Main results 
 Patients who did not start preventive treatment used 
less triptans per month compared with patients who 
started preventive treatment, whereas the two groups 
did not diff er in HIT-6 score, attack frequency, and head-
ache days per month. In addition, patients who did not 
start preventive treatment had a lower level of psycho-
logical distress, which may indicate that their coping 
with headaches was better and that their wellbeing was 
less infl uenced by headaches. 
 Table I. Comparison between migraine patients who did not and those who did start preventive treatment. 
Evaluation consultation, 
but did not start 
preventive treatment 
( n    43)
Evaluation consultation 
and started preventive 
treatment 
( n    32)  P -value
Female (%) 88.1 93.8 0.41
Age in years 47.1 (10.4) 49.2 (11.3) 0.42
Number of triptans per month 3.6 (1.8) 6.8 (4.4) 0.00
Number of consultations for 
headache last year
0.43 (0.80) 0.45 (0.78) 0.94
HIT-6 score 61.2 (5.2) 62.8 (3.4) 0.14
K10 score 18.6 (5.8) 20.9 (6.3) 0.11
Number of attacks per month a 3.2 (1.3) 3.8 (1.6) 0.12
Headache days b 3.8 (2.1) 4.9 (4.4) 0.20
Paid work (hours per week) 21.4 (15.4) 18.0 (16.7) 0.36
Absence from work (days per month) 1.1 (0.6) 1.0 (1.4) 0.88
 Numbers are means (SD) unless stated otherwise. 
 a Attacks of maximum 72 h, attacks recurring within 24 h are considered as a recurrence of the earlier attack. 
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of all issues that play a role in decisions on preventive 
medication. However, this is the fi rst study to ask 
migraine patients about their reasons for not starting 
preventive treatment in a natural setting, rather than 
confronting them with a hypothetical situation (12,16). 
 Second, the starting point for this pragmatic trial was 
the number of triptans used, rather than diagnosis of 
migraine headache. This could have led to the inclusion 
of participants that did not suff er from migraine head-
aches, or had a combination of diff erent forms of 
headache for which preventive treatment was not 
appropriate. 
 Third, the results may be subject to recall bias. GPs 
and patients may have had diffi  culty in remembering the 
exact reasons for not starting preventive treatment. 
 Comparison with other studies 
 The present study shows that, in addition to migraine 
characteristics such as duration and frequency, and the 
impact of the migraine attacks on daily life, also fear of 
side-eff ects and a negative attitude towards medication 
in general play a role in a patient ’ s decision about start-
ing preventive treatment. This corresponds with earlier 
 In almost 50% of patients with an indication for 
preventive treatment, this option was not discussed. 
When it was discussed, the decision to start actually pre-
ventive treatment was mainly infl uenced by patients ’ 
attitudes towards medication in general, possible side-
eff ects, and the impact of migraine on their daily life. The 
latter reason is noteworthy, because patients who did 
not start preventive treatment did not diff er from 
patients who did in score on the HIT-6 questionnaire, 
attack frequency and headache days. Therefore, the 
decision regarding whether to start preventive treat-
ment seems to depend more on how patients evaluate 
their condition than on objective measures. 
 The main reason for physicians not to discuss the 
option of preventive treatment was their low expecta-
tion of effi  cacy. When they did discuss preventive treat-
ment, they were often confronted with barriers in the 
patients themselves. 
 Study limitations 
 First, the number of patients is relatively small because 
it was an explorative study within the setting of a trial. 
Therefore, we do not claim to give a complete overview 
 Table II. Reasons given by migraine patients ( n    31) and general practitioners (GPs) (regarding 33 patients) for not discussing, or having discussed 
but not starting, preventive migraine treatment. 
 Patients General practitioners
Not discussed
 n    18
(%)
Not started
 n    13
(%)
Not discussed
 n    8
(%)
Not started
 n    25
(%)
Reasons for both patient and GP
Negative attitude towards drugs in general 1 (5.3) 5 (14.3) a 0 (0) 0 (0)
Possible adverse eff ects 1 (5.4) 5 (14.3) a 0 (0) 2 (5.0)
Migraine attacks not severe enough 3 (15.8) 5 (14.3) a 0 (0) 6 (15.0)
Attack treatment could be improved 2 (10.5) 2 (5.7) 2 (20.0) 3 (7.5)
Infl uence of migraine on daily life acceptable 3 (15.8) 5 (14.3) a 0 (0) 0 (0)
Expected to forget to take preventive treatment 0 (0) 0 (0) 1 (10.0) 0 (0)
Tried preventive treatment in the past 4 (21.1) a 5 (14.3) a 0 (0) 2 (5.0)
Did not expect eff ect of preventive treatment 
 on severity or frequency of attacks
0 (0) 0 (0) 4 (40.0) a 1 (2.5)
Want to try other treatment fi rst 2 (10.5) 5 (14.3) a 2 (20.0) 3 (7.5)
Otherwise, namely:
 The attacks were not frequent enough 0 (0.0) 1 (2.9) 0 (0) 4 (10.0)
 Decline of attack frequency after menopause 2 (10.5) 1 (2.9) 0 (0) 2 (5.0)
Reasons given only by patients
 Did not expect to be able to function better 0 (0) 0 (0) n/a n/a
 Makes me feel like I have a chronic illness 0 (0) 1 (2.9) n/a n/a
 GP objected to preventive treatment 0 (0) 0 (0) n/a n/a
 I thought the GP should raise the subject 1 (5.3) n/a n/a n/a
Reasons given only by GPs
 I thought the patient should raise the subject n/a n/a 0 (0) 0 (0)
Otherwise, namely:
 Patient did not show up for consultation n/a n/a 1 (10.0) 0 (0)
 Patient was content with treatment n/a n/a 0 (0) 8 (20.0) a 
 Patient had objections about preventive therapy n/a n/a 0 (0) 8 (20.0) a 
 Patient had doubts about the diagnosis n/a n/a 0 (0) 1 (2.5)
Total 19 35 10 40
 Numbers between brackets indicate the percentage of respondents mentioning that particular reason. 
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 The main reason for physicians to discuss not even 
preventive treatment was their low expectation of effi  -
cacy. This corresponds with the fi ndings in a focus group 
study with GPs that explored ideas, motives and expecta-
tions of GPs in relation to preventive treatment of 
migraine patients (21). 
 In this study, the main reason for GPs not to start 
preventive treatment was barriers present in patients. 
studies showing that important factors in the decision 
are eff ectiveness of an agent, general fear of new inter-
ventions on their health problem, fear of side-eff ects, 
drug dependency or fear of becoming a chronic patient, 
involvement in the decision-making process, and 
the physician taking the time to explain possible side-
eff ects (17 – 20). Thus, the present study confi rms earlier 
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Thus, the patient seems to play the main role in the deci-
sion to start or not to start. A study among patients at 
high risk for cardiovascular disease showed that their 
willingness to take preventive medication depended 
more on the mode of communication of treatment 
benefi t than on their actual risk score or their level of 
concern about a future cardiovascular event (22). 
 Implications for clinical practice 
 In patients who seem good candidates for preventive 
treatment according to their attack frequency, the deci-
sion of the individual patient and their GP to start preven-
tive treatment also depends on the impact of the headache 
attacks on their daily life and their negative attitude 
towards medication. However, in most guidelines on 
migraine treatment, as well as in (postgraduate) physician 
training and patient education, these aspects receive little 
attention. Therefore, these aspects should be addressed 
in order to rectify incorrect ideas and remove potential 
barriers, in both physicians and patients. In addition, as 
the decision seems to be infl uenced by the interaction 
with the GP, physicians should devote suffi  cient time to a 
shared decision-making process. Based on these results, 
we consider that GPs should pay more attention to explor-
ing the attitudes of patients towards medication; provid-
ing adequate information about both positive and negative 
aspects may remove barriers and promote the option of 
possible eff ective preventive therapy. 
 Conclusion 
 The decision of the individual patient and their GP to 
start preventive treatment is not only determined by 
attack frequency, but also depends on the impact of the 
headache attacks on their daily life and their negative 
attitude towards medication. 
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